广东中科药物研究有限公司

Guangdong Zhongke Drug Research Co., Ltd. is a biotechnology company based in Guangzhou, China, dedicated to the discovery and development of innovative small molecule therapeutics. The company serves as a primary translational platform for the Guangzhou Institute of Biomedicine and Health (GIBH) under the Chinese Academy of Sciences. Its research focus centers on oncology, respiratory diseases, and metabolic disorders, utilizing advanced medicinal chemistry and structural biology to target protein kinases. The company is most notable for its role in the early development of olverembatinib, a third-generation BCR-ABL inhibitor. Guangdong Zhongke Drug Research continues to advance a pipeline of novel candidates targeting DDR1 and ALK for various unmet medical needs.